Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Women Health topic
No spam. Unsubscribe anytime.
Speaker cites review linking HRT started near menopause to lower cardiovascular events
Summary
In the session a participant cited a 2023 review and said starting hormone replacement therapy within ten years of menopause was associated in the review with a 48% reduction in long-term cardiovascular events and a 30% reduction in all-cause mortality.
A participant in the roundtable referenced a 2023 review (described as appearing in the literature) indicating substantial cardiovascular benefits for women who start hormone replacement therapy within ten years of menopause. The speaker said the review showed a 48% reduction in long-term cardiovascular events and a 30% reduction in all-cause mortality for that group.
The speaker framed the finding as part of recent discussions on women's health and said it highlights that heart disease is the leading cause of death in women. The participant also noted some confusion in practice and labeling around local forms of estrogen.
The comments referenced a published review rather than a new regulatory action. The speaker suggested issuing public information materials and said more public discussion of the research would follow in coming weeks.
